Moderna (MRNA)
On January 27, I addressed the growing coronavirus scare… and advised readers to pay attention to Moderna, a recent IPO with promising technology… and a lot to prove.
Despite being one of the largest biotech IPOs on record, relatively few people had ever heard of it.
Now, it’s a household name.
Five weeks ago, on December 18, Moderna’s COVID-19 vaccine was granted emergency approval by the Food and Drug Administration (FDA). It was the second vaccine to receive such approval, only after the Pfizer-BioNTech vaccine, approved a week earlier.
The vaccine requires two shots just like Pfizer’s, but it has one significant advantage: it doesn’t require ultra-cold temperatures for storage.